Patrick Fabbio - Jan 30, 2023 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Role
Chief Financial Officer
Signature
/s/ Mary Grendell, Attorney-in-Fact
Stock symbol
TARA
Transactions as of
Jan 30, 2023
Transactions value $
$0
Form type
4
Date filed
1/30/2023, 03:52 PM
Previous filing
Dec 23, 2022
Next filing
Jan 23, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARA Stock Option (Right to Buy) Award $0 +300K $0.00 300K Jan 30, 2023 Common Stock 300K $3.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares shall vest on January 30, 2024 and the remainder of the shares will vest in a series of thirty-six successive equal monthly installments measured from January 30, 2024, subject to the Reporting Person's Continuous Service (as defined in the Company's 2020 Inducement Plan) with the Issuer through each such vesting date.